A pilot study of stereotactic boost for malignant epidural spinal cord compression: clinical significance and initial dosimetric evaluation

• Published in: Radiation oncology (London, England) Vol. 15; no. 1; pp. 1 - 267
• Main Authors: Donovan, Elysia K, Greenspoon, Jeffrey, Schnarr, Kara L, Whelan, Timothy J, Wright, James R, Hann, Crystal, Whitton, Anthony, Chow, Tom, Parpia, Sameer, Swaminath, Anand
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 18.11.2020; BioMed Central; BMC
• Subjects: Care and treatment; Clinical significance; Clinical trials; Complications; Complications and side effects; Compression; Compression tests; Decompression; Development and progression; Dosimetry; Epidural; Esophagus; Feasibility studies; Magnetic resonance imaging; Malignancy; Metastases; Metastasis; Methods; Motor task performance; Neurological complications; Pain; Palliative radiation; Patient outcomes; Patients; Protocol (computers); Quality assurance; Quality of life; Radiation; Radiation therapy; Radiotherapy; Simulation; Spinal cord; Spinal cord compression; Stereotactic radiotherapy; Study Protocol; Surgery; Canada
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-020-01710-4

Abstract Purpose Metastatic epidural spinal cord compression (MESCC) is a devastating complication of advanced malignancy, which can result in neurologic complications and significant deterioration in overall function and quality of life. Most patients are not candidates for optimal surgical decompression and as a result, receive urgent 3D conformal radiotherapy (3DCRT) to prevent or attempt to reverse neurologic progression. Multiple trials indicate that response and ambulatory rates after 3DCRT are inferior to surgery. The advent of stereotactic body radiation therapy (SBRT) has created a method with which a “radiosurgical decompression” boost may facilitate improve outcomes for MESCC patients. Methods We are conducting a pilot study to investigate SBRT boost after urgent 3D CRT for patients with MESCC. The aim of the study is to establish feasibility of this two-phase treatment regimen, and secondarily to characterize post-treatment ambulation status, motor response, pain control, quality of life and survival. Discussion We describe the study protocol and present a case report of one patient. A quality assurance review was conducted after the first seven patients, and resultant dose-constraints were revised to improve safety and feasibility of planning through more conservative organ at risk constraints. There have been no severe adverse events (grade 3–5) to date. We have illustrated clinical and dosimetric data of an example case, where a patient regained full strength and ambulatory capacity. Conclusions Our study aims to determine if SBRT is a feasible option in addition to standard 3DCRT for MESCC patients, with the goal to consider future randomized trials if successful. Having a robust quality assurance process in this study ensures translatability going forward if future trials with multicenter and increased patient representation are to be considered. Trial registration clinicaltrials.gov; registration no. NCT03529708; https://clinicaltrials.gov/ct2/show/NCT03529708 ; First posted May 18, 2018.